

Home Safety MedWatch The FDA Safety Information and Adverse Event Reporting Program Safety Information Safety Alerts for Human Medical Products Safety

Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient

ISSUE: FDA lab tests have confirmed that a counterfeit version of Roche's Altuzan 400mg/16ml (bevacizumab), an injectable cancer medication, found in the U.S. contains no active ingredient. Even if the identified drugs were not counterfeit, Altuzan is not approved by FDA for use in the United States (it is an approved drug in Turkey).

BACKGROUND: Medical practices obtained the counterfeit Altuzan and other unapproved products through foreign sources, in particular from Richards Pharma, also known as Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc (BDMI). Many, if not all, of the products sold and distributed through this distributor have not been approved by the FDA. Pictures of the counterfeit version of Altuzan are shown in the FDA statement. Packaging or vials found in the U.S. that claim to be Roche's Altuzan with lot number B6021 should be considered counterfeit.

RECOMMENDATION: Any medical practice that has obtained unapproved products, in particular from Richards Pharma, Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc (BDMI), should stop using them and contact the FDA. The products should be retained and securely stored until further notice by the FDA.

FDA is asking the public to report suspect counterfeit products and other suspect products obtained from Richards Pharma, Richards Services, Warwick Healthcare Solutions, Ban Dune Marketing Inc (BDMI), or other sources: Call FDA's Office of Criminal Investigations (OCI) at 800-551-3989, or

Visit OCI's Web site (www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm¹), or Email - DrugSupplyChainIntegrity@fda.hhs.gov

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- Complete and submit the report Online: www.fda.gov/MedWatch/report.htm²
- Download form³ or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the preaddressed form, or submit by fax to 1-800-FDA-0178

[04/03/2012 - Drug Integrity and Supply Chain Security Statement⁴ - FDA]

Page Last Updated: 05/23/2012

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | أوربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسي | English

Accessibility Contact FDA Careers FDA Basics FOIA No FEAR Act Site Map Nondiscrimination Website Policies

FDA

U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Ph. 1-888-INFO-FDA (1-888-463-6332) Contact FDA



For Government For Press

Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive



U.S. Department of Health & Human Services

Links on this page:

- 1. /web/20170112164830/http://www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm
- 2. /web/20170112164830/http://www.fda.gov/MedWatch/report.htm

WayBack Machine

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHi Go DEC JAN FEI

19 captures
5 Apr 12 - 12 Jan 17